Skip to content

2APharma

Biopharmaceutical company

  • Home
  • ABOUT US
  • VACCINE PLATFORM
  • PIPELINE
    • OVERVIEW
    • 2AP01
    • 2AP02
    • 2AP03
    • 2AP05
    • 2AP07
  • NEWS
  • CONTACT US

June 4, 2020

2AP04

OVERVIEW:

  • Induces A𝛽 specific antibodies recognizing monomeric and aggregated forms of human amyloid-beta
  • Decreases levels of soluble A𝛽 peptides and plaque load in brain of hAPP transgenic mice
  • BLANK

    2A Pharma’s anti-amyloid-beta vaccine candidate, AAVLP-Amyloid-β, has in laboratory tests with transgenic mice over-expressing amyloid-beta mutant protein been shown to eliminate amyloid-beta soluble protein, a clear plaque from the cortex and significantly reduce plaque from the hippocampus.

    It is our hope that the drug candidate can be developed into a treatment for early-stage Alzheimer’s disease.

    Back

    Denmark

    2A Pharma ApS
    Niels Jernes Vej 10
    9220 Aalborg Øst
    Denmark

    CVR No.: 3939 1597
    VAT No.: DK 3939 1597

    Sweden

    2A Pharma AB
    Södergatan 3
    211 34 Malmö
    Sweden

    Registration No.: 559090-2788
    VAT No.: SE55 9090 2788 01

    Pipeline

  • 2AP01 HPV
  • 2AP02 Breast Cancer
  • 2AP03 Allergic Diseases
  • 2AP04 Alzheimer's
  • 2AP05 Autoimmune Diseases
  • 2AP06 HIV
  • 2AP07 Head and Neck Cancer
  • Subscribe to our newsletters

    Contact

    +45 7214 6700
    info@2apharma.com